The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program "CASCADE"

More about Open Access at the Crick

Abstract

Understanding the cancer genome is seen as a key step in improving outcomes for cancer patients. Genomic assays are emerging as a possible avenue to personalised medicine in breast cancer. However, evolution of the cancer genome during the natural history of breast cancer is largely unknown, as is the profile of disease at death. We sought to study in detail these aspects of advanced breast cancers that have resulted in lethal disease.